Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011;32:1107–21.
   PubMed Web of Science ®Google Scholar
• Stewart BW, Wild CP. World Cancer Report, Lyon, France: IARC Publications; ; 2014.
   Google Scholar
• Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384–91.
   PubMed Web of Science ®Google Scholar
• Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012;56:704–13.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Carr BI, Cavallini A, Lippolis C, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013;228:292–7.
   PubMed Web of Science ®Google Scholar
• Kissel M, Berndt S, Fiebig L, et al. Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 2017;8:107096–108.
   PubMedGoogle Scholar
• Unsal H, Yakicier C, Marcais C, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994;91:822–6.
   PubMed Web of Science ®Google Scholar
• De Sousa EMF, Vermeulen L, Fessler E, et al. Cancer heterogeneity-a multifaceted view. EMBO Rep 2013;14:686–95.
   PubMed Web of Science ®Google Scholar
• Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155–76.
   PubMed Web of Science ®Google Scholar
• Sysak A, Obminska-Mrukowicz B. Isoxazole ring as a useful scaffold in a search for new therapeutic agents. Eur J Med Chem 2017;137:292–309.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850–60.
   PubMed Web of Science ®Google Scholar
• Felip E, Barlesi F, Besse B, et al. Brief report: phase 2 study of the HSP-90 inhibitor AUY922 in previously treated and molecularly defined patients with advanced non-small cell lung cancer. J Thorac Oncol 2018;13(4):576–84.
   Google Scholar
• Zhang C, Chu M. Leflunomide: a promising drug with good antitumor potential. Biochem Biophys Res Commun 2018;496(2):726–30.
   PubMed Web of Science ®Google Scholar
• Kaffy J, Pontikis R, Carrez D, et al. Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. Bioorg Med Chem 2006;14:4067–77.
   PubMed Web of Science ®Google Scholar
• Kamal A, Bharathi EV, Reddy JS, et al. Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents. Eur J Med Chem 2011;46:691–703.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Diallo H, Goodacre JD, et al. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J Med Chem 2012;55:587–96.
   PubMed Web of Science ®Google Scholar
• Chung CW, Dean AW, Woolven JM, et al. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem 2012;55:576–86.
   PubMed Web of Science ®Google Scholar
• Hewings DS, Fedorov O, Filippakopoulos P, et al. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem 2013;56:3217–27.
   PubMed Web of Science ®Google Scholar
• Hewings DS, Wang M, Philpott M, et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 2011;54:6761–70.
   PubMed Web of Science ®Google Scholar
• Robles AJ, McCowen S, Cai S, et al. Structure-activity relationships of new natural product-based diaryloxazoles with selective activity against androgen receptor-positive breast cancer cells. J Med Chem 2017;60:9275–89.
   PubMed Web of Science ®Google Scholar
• Akkoc MK, Yuksel MY, Durmaz I, et al. Design, synthesis, and biological evaluation of indole-based 1,4-disubstituted piperazines as cytotoxic agents. Turk J Chem 2012;36:515–25.
   Web of Science ®Google Scholar
• Mao ZW, Zheng X, Qi Y, et al. Synthesis and biological evaluation of novel hybrid compounds between chalcone and piperazine as potential antitumor agents. Rsc Adv 2016;6:7723–7.
   Web of Science ®Google Scholar
• Saab AM, Dobmeier M, Koenig B, et al. Antiproliferative and erythroid differentiation of piperazine and triphenyl derivatives against k-562 human chronic myelogenous leukemia. Anticancer Res 2013;33:3027–32.
   PubMed Web of Science ®Google Scholar
• Tuncbilek M, Guven EB, Onder T, et al. Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(beta-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells. J Med Chem 2012;55:3058–65.
   PubMed Web of Science ®Google Scholar
• Waszkielewicz AM, Gunia A, Szkaradek N, et al. Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety. Bioorg Med Chem Lett 2013;23:4419–23.
   PubMed Web of Science ®Google Scholar
• Hori Y, Ishii K, Kanda H, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila) 2011;4:87–96.
   PubMed Web of Science ®Google Scholar
• Kanda H, Ishii K, Ogura Y, et al. Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer 2008;122:444–51.
   PubMed Web of Science ®Google Scholar
• Chen H, Liang X, Xu F, et al. Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Molecules 2014;19:12048–64.
   PubMed Web of Science ®Google Scholar
• Chen H, Xu BB, Sun T, et al. Synthesis and antitumor activity of novel arylpiperazine derivatives containing the saccharin moiety. Molecules 2017;22(11):1857.
   Web of Science ®Google Scholar
• Chen H, Xu F, Liang X, et al. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Bioorg Med Chem Lett 2015;25:285–7.
   PubMed Web of Science ®Google Scholar
• Cho EH, Chung SG, Lee SH, et al. Piperazine derivatives and process for the preparation thereof, Patent WO1998000402, A1;1998.
   Google Scholar
• Lee JH, Kang DW, Kwon HS, et al. Microtubule inhibitory effects of various SJ compounds on tissue culture cells. Arch Pharm Res 2004;27:436–41.
   PubMed Web of Science ®Google Scholar
• Rathi AK, Syed R, Shin HS, et al. Piperazine derivatives for therapeutic use: a patent review (2010-present). Expert Opin Ther Pat 2016;26:777–97.
   PubMed Web of Science ®Google Scholar
• Banoglu E, Caliskan B, Luderer S, et al. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). Bioorg Med Chem 2012;20:3728–41.
   PubMed Web of Science ®Google Scholar
• Banoglu E, Celikoglu E, Volker S, et al. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP). Eur J Med Chem 2016;113:1–10.
   PubMed Web of Science ®Google Scholar
• Baytas SN, Inceler N, Yilmaz A, et al. Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors. Bioorg Med Chem 2014;22:3096–104.
   PubMed Web of Science ®Google Scholar
• Caliskan B, Yilmaz A, Evren I, et al. Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3(5)-carboxylic acid derivatives. Med Chem Res 2013;22:782–93.
   Web of Science ®Google Scholar
• Cankara Pirol S, Caliskan B, Durmaz I, et al. Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines. Eur J Med Chem 2014;87:140–9.
   PubMed Web of Science ®Google Scholar
• Irmak MB, Ince G, Ozturk M, et al. Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism? Cancer Res 2003;63:6707–15.
   PubMed Web of Science ®Google Scholar
• Bindokas VP, Jordan J, Lee CC, et al. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci 1996;16:1324–36.
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar
• Solly K, Wang X, Xu X, et al. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004;2:363–72.
   PubMed Web of Science ®Google Scholar
• System Xcelligence. Real-time and dynamic monitoring of cell proliferation and viability for adherent cells. Application Note 1. San Diego, CA: Acea Biosciences Inc.; 2013.
   Google Scholar
• Durmaz I, Guven EB, Ersahin T, et al. Liver cancer cells are sensitive to lanatoside C induced cell death independent of their PTEN status. Phytomedicine 2016;23:42–51.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer 2017;16:79.
   PubMed Web of Science ®Google Scholar
• Nogueira V, Park Y, Chen CC, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008;14:458–70.
   PubMed Web of Science ®Google Scholar
• Buontempo F, Ersahin T, Missiroli S, et al. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. Invest New Drugs 2011;29:1303–13.
   PubMed Web of Science ®Google Scholar
• Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 2010;277:2–21.
   PubMed Web of Science ®Google Scholar
• Sheahan S, Bellamy CO, Treanor L, et al. Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene 2004;23:1489–97.
   PubMed Web of Science ®Google Scholar